| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM21 |
| Uniprot No | P19474 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-475aa |
| 氨基酸序列 | MASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEAREGTQGERCAVHGERLHLFCEKDGKALCWVCAQSRKHRDHAMVPLEEAAQEYQEKLQVALGELRRKQELAEKLEVEIAIKRADWKKTVETQKSRIHAEFVQQKNFLVEEEQRQLQELEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSSALELLQEVIIVLERSESWNLKDLDITSPELRSVCHVPGLKKMLRTCAVHITLDPDTANPWLILSEDRRQVRLGDTQQSIPGNEERFDSYPMVLGAQHFHSGKHYWEVDVTGKEAWDLGVCRDSVRRKGHFLLSSKSGFWTIWLWNKQKYEAGTYPQTPLHLQVPPCQVGIFLDYEAGMVSFYNITDHGSLIYSFSECAFTGPLRPFFSPGFNDGGKNTAPLTLCPLNIGSQGSTDY |
| 预测分子量 | 57.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于TRIM21重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*TRIM21 is an IgG receptor that is structurally and functionally conserved in mammals*
**作者**：Leo C. James et al.
**摘要**：该研究解析了TRIM21重组蛋白的晶体结构，揭示了其与免疫球蛋白(IgG)的结合机制，并证明其在哺乳动物中通过泛素化途径介导抗体包被病毒颗粒的降解，阐明了其在先天免疫中的关键作用。
---
2. **文献名称**：*Structural basis for autoinhibition and phosphorylation-dependent activation of cGAS*
**作者**：Yue Feng et al.
**摘要**：研究通过重组TRIM21蛋白实验，证明其通过泛素化调控cGAS(环鸟苷酸-腺苷酸合成酶)的活性，抑制自身免疫反应过度激活，为抗病毒与自身免疫平衡机制提供了分子依据。
---
3. **文献名称**：*Antibody-antigen docking structures reveal non-redundant roles of TRIM21 domains in target recognition*
**作者**：Clarissa L. Waites et al.
**摘要**：利用重组TRIM21蛋白的PRY/SPRY结构域与抗原复合物结构分析，揭示了其多结构域协同识别病原体的分子机制，为开发基于TRIM21的靶向降解技术奠定基础。
---
4. **文献名称**：*TRIM21-dependent intracellular antibody neutralization of virus infection*
**作者**：Edward M. Campbell et al.
**摘要**：通过体外重组TRIM21蛋白实验，证明其结合抗体后激活蛋白酶体途径降解病毒颗粒，提出了“细胞内抗体免疫”新概念，为抗病毒治疗策略提供新方向。
---
以上文献均聚焦于TRIM21重组蛋白的结构、功能及其在免疫调控中的应用，涵盖泛素化、病原体识别和靶向降解等关键方向。
TRIM21 (Tripartite Motif-containing protein 21) is a multifunctional protein belonging to the TRIM family, characterized by its conserved RING, B-box, and coiled-coil domains. It also contains a C-terminal PRY-SPRY domain, which enables its role as an intracellular antibody receptor. TRIM21 is widely expressed in mammalian cells and plays a critical role in innate immunity by targeting antibody-bound pathogens, such as viruses or bacteria, for proteasomal degradation via its E3 ubiquitin ligase activity. This process, termed "ubiquitin-dependent viral neutralization," links adaptive and innate immune responses by recognizing immune complexes that enter the cytosol during infection.
Recombinant TRIM21 proteins are engineered versions of the native protein, often produced in bacterial or mammalian expression systems for research and therapeutic applications. These proteins retain key functional domains, allowing scientists to study their interactions with immunoglobulins (IgG or IgM), ubiquitination mechanisms, and antiviral defense pathways in vitro. TRIM21's ability to bridge antibodies to the ubiquitin-proteasome system has also spurred interest in targeted protein degradation technologies, including PROTACs (Proteolysis-Targeting Chimeras), where it could serve as a modular component for directing disease-related proteins for destruction.
Beyond immunity, TRIM21 regulates cellular processes like autophagy, apoptosis, and inflammation, making its recombinant forms valuable tools for exploring these pathways. Dysregulation of TRIM21 has been implicated in autoimmune diseases (e.g., lupus) and cancer, highlighting its therapeutic potential. Researchers continue to optimize recombinant TRIM21 variants to enhance stability, specificity, and delivery for biomedical applications, positioning it as a versatile molecule at the intersection of immunology, molecular engineering, and drug development.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
